Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature

Chemotherapy agents for patients with metastatic castration-resistant prostate cancer (mCRPC) include docetaxel and cabazitaxel. Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge. We, here, repor...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore)
Main Authors: Di Lorenzo, Giuseppe, Pagliuca, Martina, Perillo, Teresa, Benincasa, Alfonso, Bosso, Davide, De Placido, Sabino, Buonerba, Carlo
Format: Artigo
Language:Inglês
Published: Wolters Kluwer Health 2016
Subjects:
5700
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998742/
https://ncbi.nlm.nih.gov/pubmed/27057826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002754
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items